Bempedoic acid (brand name: Nexletol), already FDA-approved for cholesterol, is being tested in PKD based on its ability to activate AMPK — the same pathway that metformin targets.
Background
Bempedoic acid received FDA approval in 2020 for lowering LDL cholesterol. But researchers at the University of Vermont discovered it has a second, potentially more relevant property for PKD patients: it's a potent AMPK activator. Crucially, bempedoic acid is a pro-drug that gets activated specifically in the liver and kidney — exactly where PKD patients need it. The BEAT-PKD trial, funded by the Department of Defense, will test whether this targeted AMPK activation can slow cyst growth.
How It Works
Bempedoic acid inhibits ATP citrate lyase (ACLY), an enzyme upstream of HMG-CoA reductase. This inhibition activates AMPK (AMP-activated protein kinase). In PKD, AMPK activation inhibits mTOR (reducing cell proliferation) and CFTR chloride channels (reducing cyst fluid secretion). Unlike metformin, which activates AMPK throughout the body, bempedoic acid's activation is tissue-specific to liver and kidney, potentially offering fewer side effects like GI issues.
Clinical Trial Details
The BEAT-PKD trial (NCT07282821) is a Phase 2, randomized, double-blind, placebo-controlled study of 120 ADPKD patients receiving 180mg bempedoic acid daily for 2 years. Primary endpoint is TKV change by MRI. Funded by the U.S. Department of Defense. Expected to begin recruiting July 2026 with completion in 2028.
Why It's Promising
Since bempedoic acid is already FDA-approved and has a well-established safety profile, successful results could lead to rapid adoption (off-label prescribing could begin immediately). The kidney-specific activation is a major advantage over metformin. If BEAT-PKD succeeds, it could reach widespread use within 3–5 years.
Limitations & Concerns
Not yet recruiting as of mid-2026. AMPK activation is a shared mechanism with metformin — if IMPEDE-PKD (metformin Phase 3) fails, it may cast doubt on this pathway. The 2-year timeline is short for PKD progression studies.